


PRODUCT INFORMATION



FH535

Item No. 18001

CAS Registry No.: 108409-83-2
Formal Name: 2,5-dichloro-N-(2-methyl-4-nitrophenyl)-benzenesulfonamide
MF: C₁₃H₁₀Cl₂N₂O₄S
FW: 361.2
Purity: ≥95%
UV/Vis.: λ_{max}: 292 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

FH535 is supplied as a crystalline solid. A stock solution may be made by dissolving the FH535 in the solvent of choice, which should be purged with an inert gas. FH535 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of FH535 in these solvents is approximately 10 and 25 mg/ml, respectively.

FH535 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, FH535 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. FH535 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

FH535 is an inhibitor of β -catenin/Tcf-mediated transcription and an antagonist of ligand-dependent activation of PPAR γ and PPAR δ .¹ At 15 μ M, FH535 blocks the recruitment of β -catenin and GRIP1 to PPAR γ and PPAR δ .¹ Presumably through these actions, FH535 is selectively toxic to some carcinoma cell lines expressing the Wnt/ β -catenin pathway.¹ FH535 is used to study the role of Wnt/ β -catenin pathway in various cancer cell lines.²⁻⁴

References

1. Handeli, S. and Simon, J.A. A small-molecule inhibitor of Tcf/ β -catenin signaling down-regulates PPAR γ and PPAR δ activities. *Mol. Cancer Ther.* **7(3)**, 521-529 (2008).
2. Faisy, C., Grassin-Delyle, S., Blouquit-Laye, S., et al. Wnt/ β -catenin signaling modulates human airway sensitization induced by β_2 -adrenoceptor stimulation. *PLoS One* **9(10)**, (2014).
3. Su, H., Jin, X., Zhang, X., et al. FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R. *J. Transl. Med.* **13:104**, (2015).
4. Wu, M.-Y., Liang, R.-R., Chen, K., et al. FH535 inhibited metastasis and growth of pancreatic cancer cells. *Oncotargets and Therapy* **8**, 1651-1670 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM